Wednesday, March 01, 2023
Oragenics announced that the Company has entered into an exclusive global licence agreement with Inspirevax for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
Under the exclusive licencing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax’s novel BDX301 intranasal mucosal adjuvant. Additionally, the agreement provides a certain period of time for the companies to expand collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.
This agreement is an important milestone in expanding development opportunities for Oragenics and for company's strategic initiatives. This collaboration with experts of Inspirevax enables to pursue the development of novel intranasal vaccine candidates.
Intranasally delivered vaccines with BDX301 adjuvant have shown encouraging results in preclinical models for COVID-19 infections. This partnership with Oragenics’ ensures for the development of a potential novel intranasal vaccine candidate in the global fight against COVID-19 and infectious disease.
